Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) Director Alan M. Garber sold 19,205 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $24.01, for a total value of $461,112.05. Following the completion of the sale, the director now directly owns 35,703 shares of the company’s stock, valued at approximately $857,229.03. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Exelixis Price Performance
Shares of NASDAQ:EXEL opened at $23.86 on Thursday. The business’s fifty day moving average price is $21.99 and its two-hundred day moving average price is $21.97. Exelixis, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $24.34. The stock has a market capitalization of $7.23 billion, a price-to-earnings ratio of 37.28, a price-to-earnings-growth ratio of 0.62 and a beta of 0.53.
Exelixis (NASDAQ:EXEL – Get Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. The firm had revenue of $479.65 million for the quarter, compared to analysts’ expectations of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. Research analysts expect that Exelixis, Inc. will post 1.22 EPS for the current fiscal year.
Institutional Trading of Exelixis
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the company. Stifel Nicolaus boosted their target price on Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Royal Bank of Canada boosted their target price on Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. BTIG Research assumed coverage on Exelixis in a report on Tuesday, December 19th. They issued a “buy” rating and a $27.00 target price for the company. Citigroup assumed coverage on Exelixis in a report on Friday, December 15th. They issued a “buy” rating and a $31.00 target price for the company. Finally, TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a report on Monday, March 18th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $26.29.
Read Our Latest Analysis on Exelixis
Exelixis Company Profile
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Recommended Stories
- Five stocks we like better than Exelixis
- How to Capture the Benefits of Dividend Increases
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Bank Stocks – Best Bank Stocks to Invest In
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Investing In Automotive Stocks
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.